CD19-targeted third-generation CAR T cells

CD19-targeted third-generation CAR T cells are autologous or allogeneic T cells genetically engineered to express a chimeric antigen receptor (CAR) that specifically targets the CD19 antigen, which is present on malignant and normal B cells. These third-generation CARs combine antigen recognition (usually through an scFv targeting CD19) with two co-stimulatory domains (typically CD28 and 4-1BB), and a CD3 zeta signaling domain, thereby enhancing T cell activation, persistence, and antitumor efficacy compared to earlier generations. They are primarily studied as immunotherapy for relapsed or refractory B-cell hematologic malignancies, including acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), and B-cell lymphomas. Multiple academic institutions and centers have developed and manufactured third-generation CD19 CAR T cell products for clinical trials, most notably for patients who have failed prior therapies. The primary mechanism is targeted killing of CD19-positive B cells via T cell-mediated cytotoxicity, often resulting in B-cell aplasia as an on-target effect[1][3][4][7].

Other names

HD-CAR-1HD-CAR1HD-CAR 1third-generation CD19 CAR T cellsCD19-targetingCD-19-targetingCD 19-targeting3rd Generation CAR T Cells